Dublin, 31 Dec. 2021 (GLOBE NEWSWIRE) — The “Chinese Capecitabine Market Survey Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.
Capecitabine is a pyrimidine (pentoxycarbonyl-deoxy-cytosine nucleoside) analog that has anti-tumor activity to inhibit a variety of solid tumors including breast and colon cancer. Capecitabine was developed by Roche. Its product, XELODA, was cleared to enter the Chinese market in 2001. By 2020, there are several manufacturers in the capecitabine market in China.
According to the market research, the sales of Capecitabine in the Chinese market increased year-on-year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on the overall diagnostic and hospital treatment, sales in 2020 decreased to CNY 914 million. , a year-over-year decline of 9.31%. The CAGR of capecitabine sales in the Chinese market from 2016 to 2020 is 1.21%.
The analyst expects that with the easing of the COVID-19 pandemic, capecitabine sales in the Chinese market will experience restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million and the number of colon cancers reached 1.93 million, both on the rise.
The number of breast and colon cancers in China will also increase in the future. Therefore, the sales volume of Capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase with the increasing number of breast and colon cancer patients in China.
There is also room for sales to increase. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already applied for approval of the generic drug Capecitabine. In the next few years, more manufacturers will join the Chinese market. Sales volume and sales of Capecitabine in China are expected to increase.
- The impact of COVID-19 on the Chinese capecitabine market
- Capecitabine sales value in China 2016-2020
- Competitive Landscape of China Capecitabine Market
- capecitabine price in china
- Capecitabine Price in China by Regions and Manufacturers
- Analysis of factors affecting the development of the Chinese capecitabine market
- China Capecitabine Market Outlook from 2021 to 2025
Main topics covered:
1 Relevant concepts of capecitabine
1.1 Indications for capecitabine
1.2 China Capecitabine Development History
1.3 Capecitabine Approval Information in China
1.4 The impact of COVID-19 on Capecitabine sales in China
2 China Capecitabine Sales, 2016-2020
2.1 Capecitabine Sales Value
2.1.1 Overall sales value
2.1.2 Sales Value by Region
2.2 Capecitabine Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 China Capecitabine Sales by Dosage Form, 2016-2020
2.3.2 Analysis of other dosage forms
3 Analysis of Capecitabine Key Manufacturers in China, 2016-2020
3.1 Capecitabine Key Manufacturers Market Share Analysis
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shanghai Roche Pharmaceuticals Co., Ltd.
3.2.1 Company profile
3.2.2 XELODA (Shanghai Roche Pharmaceuticals Co., Ltd. Capecitabine) Sales in China
3.3 Jiangsu Heng Rui Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 China Aibin (Jiangsu Hengrui Medicine Co,.Ltd. Capecitabine) Sales
3.4 Qilu Pharmaceutical Co., Ltd.
3.4.1 Company Profile
3.4.2 China Zuolun (Capecitabine by Qilu Pharmaceutical Co., Ltd.) Sales
3.5 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.5.1 Business Profile
3.5.2 China Shoufu (Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Capecitabine) Sales
3.6 Hoffmann-La Roche Inc.
3.6.1 Company Profile
3.6.2 XELODA (Capecitabine by Hoffmann-La Roche Inc) Sales in China
4 Capecitabine Price by Different Manufacturers in China, 2020-2021
4.1 Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
4.2 Jiangsu Hengrui Medicine Co,.Ltd. (Aibin)
4.3 Qilu Pharmaceutical Co., Ltd. (Zuolun)
4.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
4.5 Hoffmann-La Roche Inc (XELODA)
5 China Capecitabine Drug Market Outlook, 2021-2025
5.1 Influencing Factors of China Capecitabine Market Development
5.1.1 The impact of COVID-19 on the Chinese capecitabine market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
- Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
- Jiangsu Hengrui Medicine Co,.Ltd. (Aibin)
- Qilu Pharmaceutical Co., Ltd. (Zuolun)
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
- Hoffmann-La Roche Inc (XELODA)
For more information on this report, visit https://www.researchandmarkets.com/r/d45er9